[ampdepolymerase]

> What differentiates SpaceX from NASA, or SpaceX from Blue Origin, is people and culture. We are not trying to build an institute or academic minded organization where papers are more important than products. Our goal is to build an ambitious, well run, for-profit company that will deliver revenue generating products on the way toward accomplishing its much bigger objective.

It is debatable whether they truely understand the financials of biotech. The grind of basic research will never go away. Many successful biotech company essentially acquihire researchers and work that is already 80% complete, the role of the company is to bring it to production. That itself will make up the bulk of the company's workload. Similarly, SpaceX had the benefit of leveraging an existing pool of talent and resources; you cannot build a heavy launch company in Zimbabwe. If they want to do both active basic research and at the same time trial therapies, then they would need an enormous amount of funding (on the software unicorn level). You will need scale on the same magnitude as Pharma giants like Pfizer, GlaxoSmithKline, Johnson and Johnson to be able to acquire companies, run trials, and discard ideas that do not work. In the current bull market, this is the perfect company to build with Coinbase's founder as the chief fundraiser.